Elagolix Sodium,estradiol,norethindrone Acetate; Elagolix Sodium Patent Expiration
Elagolix Sodium,Estradiol,Norethindrone Acetate; Elagolix Sodium is Used for managing heavy menstrual bleeding associated with uterine leiomyomas (fibroids) with the use of elagolix and omeprazole. It was first introduced by Abbvie Inc
Elagolix Sodium,estradiol,norethindrone Acetate; Elagolix Sodium Patents
Given below is the list of patents protecting Elagolix Sodium,estradiol,norethindrone Acetate; Elagolix Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Oriahnn (copackaged) | US10881659 | Methods of treating heavy menstrual bleeding | Mar 14, 2034 | Abbvie |
| Oriahnn (copackaged) | US11045470 | Methods of treating heavy menstrual bleeding | Mar 14, 2034 | Abbvie |
| Oriahnn (copackaged) | US11459305 | Processes for the preparation of uracil derivatives | Nov 07, 2028 | Abbvie |
| Oriahnn (copackaged) | US11542239 | Elagolix sodium compositions and processes | Jul 23, 2039 | Abbvie |
| Oriahnn (copackaged) | US11690845 | Methods of administering elagolix | Aug 27, 2040 | Abbvie |
| Oriahnn (copackaged) | US6872728 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan 25, 2021
(Expired) | Abbvie |
| Oriahnn (copackaged) | US7056927 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | Sep 10, 2024 | Abbvie |
| Oriahnn (copackaged) | US7179815 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Mar 07, 2021
(Expired) | Abbvie |
| Oriahnn (copackaged) | US7419983 | Gonadotropin-releasing hormone receptor antagonists and methods related thereto | Jul 06, 2029 | Abbvie |
| Oriahnn (copackaged) | US7462625 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan 25, 2021
(Expired) | Abbvie |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳